Vicore Pharma (VICO.ST) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Vicore Pharma is an innovative, clinical-stage biopharma company dedicated to developing transformative treatments by selectively activating the protective angiotensin II type 2 (AT2) receptor. Its core achievement is advancing buloxibutid, a first-in-class oral AT2 receptor agonist, into a pivotal 52-week global Phase 2b trial (ASPIRE) in Idiopathic Pulmonary Fibrosis (IPF), supported by Orphan Drug and Fast Track designations. The company's strategy is to validate its ATRAG platform in IPF as a proof-of-concept, aiming to unlock its broad therapeutic potential across multiple fibrotic and inflammatory diseases while exploring strategic partnerships for pipeline expansion.

Idiopathic Pulmonary FibrosisFibrotic DiseasesRespiratory Diseases

Technology Platform

Proprietary platform of oral, small-molecule Angiotensin II Type 2 Receptor Agonists (ATRAGs) designed to activate the protective, reparative arm of the renin-angiotensin system to produce anti-fibrotic, anti-inflammatory, and tissue-regenerative effects.

Opportunities

A successful Phase 2b trial in IPF would validate the novel ATRAG platform, unlocking potential in a multi-billion dollar market and enabling expansion into other large fibrotic disease indications like systemic sclerosis and cardiac fibrosis.

The oral, disease-modifying profile could capture significant market share from current standard-of-care therapies.

Risk Factors

The primary risk is clinical failure of the lead candidate in the ongoing Phase 2b trial, which would severely impact valuation and platform credibility.

Additional risks include future capital needs leading to shareholder dilution, regulatory hurdles, and competition from other novel therapies in development for IPF and fibrosis.

Competitive Landscape

In IPF, buloxibutid directly competes with approved anti-fibrotics (nintedanib, pirfenidone) but offers a novel, reparative mechanism of action. Its primary competitive advantage is its first-in-class AT2R agonist approach, with limited direct mechanism competitors, positioning it uniquely in the broader fibrosis field dominated by anti-inflammatory and anti-fibrotic inhibitors.

More companies in Small Molecule Drugs →More companies in Sweden →